Form D · Biotechnology
Arbor Biotechnologies, Inc.
Cambridge, MA · CIK 0001707499
Offering snapshot reported Nov 10, 2021 · SEC filing
- Reported sold
- $215M Offering amount: $215M
- Investors reported
- 37 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 29, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 10, 2021 | Initial | $214,999,926 | No comparison | 37 | SEC filing |
| Aug 2, 2017 | Amendment | $15,599,998 | $3,374,999vs Jun 1, 2017 | 10 | SEC filing |
| Jun 1, 2017 | Initial | $12,224,999 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-420716
Source: Form D, filed Nov 10, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Mark Angelino | Director |
| David Cheng | Executive |
| Keith Crandell | Director |
| Rami Harawi | Director |
| Annie Hazlehurst | Director |
| Paul Meister | Director |
| Kelly Morgan | Executive |
| John Murphy | Executive |
| David Arthur Scott | Executive |
| Devyn Smith | Director, Executive |
| Pam Stetkiewicz | Executive |
| David Walt | Director |
| Winston Xia Yan | Executive |
| Chen Yu | Director |
| Feng Zhang | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
20 Acorn Park Drive Suite 500
Cambridge, MA, 02140
Cambridge, MA, 02140